MHRA-licensed alternatives for weight management including semaglutide (Wegovy), liraglutide (Saxenda), orlistat, and tirzepatide (Mounjaro) have well-characterised safety profiles and NICE eligibility criteria
Although this data analysis was performed in late 2024, there are some well-proven clinical benefits of GLP-1 medications which the researchers did not include in this model
The structural formula is: XIGDUO XR XIGDUO XR is available for oral administration as tablets containing the equivalent of 2.5 mg dapagliflozin as dapagliflozin propanediol and 1,000 mg metformin HCl which is equivalent to 779.86 mg metformin base (XIGDUO XR 2.5 mg/1,000 mg), 5 mg dapagliflozin as dapagliflozin propanediol and 500 mg metformin HCl which is equivalent to 389.9 mg metformin base (XIGDUO XR 5 mg/500 mg), the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and 1,000 mg metformin HCl which is equivalent to 779.86 mg metformin base (XIGDUO XR 5 mg/1,000 mg), the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol and 500 mg metformin HCL which is equivalent to 389.9 mg metformin base (XIGDUO XR 10 mg/500 mg), or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol and 1,000 mg metformin HCL which is equivalent to 779.86 mg metformin base (XIGDUO XR 10 mg/1,000 mg)
Therefore, many modifications have been made to GLP-1 to increase its biological half-life and consequently its efficacy in vivo
Synergistic effects of combined formulations represent an emerging area of research, with growing recognition that multi-ingredient approaches may produce benefits beyond the sum of individual components
